Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Central Nervous System Malignant Lymphoma
share announcement

Central Nervous System Malignant Lymphoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 3552

Special Issue Editors

Dr. Thomas A. Widmann

E-Mail Website
Guest Editor
Saarland University, Asklepios Klinik Triberg, Germany
Interests: cancer rehabilitation; exercise after cancer; lymphomas
Prof. Dr. Gerald Illerhaus

E-Mail Website
Co-Guest Editor
Klinikum Stuttgart, 70173 Stuttgart, Germany
Interests: primary cns lymphoma; secondary cns lymphoma; lymphoma treatment; development of new lymphoma treatment options; systemic lymphomas

Special Issue Information

Dear Colleagues,

Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder confined to the CNS. The development of high-dose methotrexate-based immune-chemotherapy in recent decades has enabled high-remission rates, and cure or multi-year progression-free survival can be obtained by consolidation strategies such as high-dose chemotherapy and autologous stem-cell transplantation.

However, this therapeutic success is offset by relevant therapy-related toxicity. Furthermore, survival deteriorates tremendously in the refractory or relapsed setting as well as in the frail population not eligible for aggressive treatment options. Secondary CNS lymphoma (SCNSL), as a rare complication of systemic non-Hodgkin lymphoma, shares this dismal prognosis. In SCNSL, optimal treatment is not established. Cellular or molecular interactions that facilitate trafficking of lymphoma cells to the CNS are pending, and risk factors detecting patients in need of MTX-based CNS prophylaxis are still a matter of debate.

Recent research has detected different molecular tumor characteristics in CNS lymphoma, potentially targetable by new substances. How these findings could translate into clinical progress, also in the context of combination therapies, must be defined.

As this abstract discloses the need for further research into the broad area of CNS lymphoma, we welcome translational and clinical research papers and reviews for this Special Issue.

Dr. Thomas A. Widmann
Prof. Dr. Gerald Illerhaus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PCNSL primary CNS lymphoma
  • secondary CNS lymphoma
  • pathogenesis
  • translational research
  • targeted therapy
  • development of new CNS lymphoma treatment options
  • high-dose chemotherapy
  • autologous stem-cell therapy
  • cancer rehabilitation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

33 pages, 592 KiB  
Systematic Review
Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
by Elisabeth Schorb, Lisa Kristina Isbell, Gerald Illerhaus, Gabriele Ihorst, Joerg J. Meerpohl, Kathrin Grummich, Blin Nagavci and Christine Schmucker
Cancers 2021, 13(17), 4268; https://doi.org/10.3390/cancers13174268 - 24 Aug 2021
Cited by 7 | Viewed by 2696
Abstract
Background: Most patients diagnosed with primary central nervous system lymphoma (PCNSL) are older than 60 years. Despite promising treatment options for younger patients, prognosis for the elderly remains poor and efficacy of available treatment options is limited. Materials and Methods: We conducted a [...] Read more.
Background: Most patients diagnosed with primary central nervous system lymphoma (PCNSL) are older than 60 years. Despite promising treatment options for younger patients, prognosis for the elderly remains poor and efficacy of available treatment options is limited. Materials and Methods: We conducted a scoping review to identify and summarize the current study pool available evaluating different types and combinations of (immuno) chemotherapy with a special focus on HCT-ASCT in elderly PCNSL. Relevant studies were identified through systematic searches in the bibliographic databases Medline, Web of Science, Cochrane Library and ScienceDirect (last search conducted in September 2020). For ongoing studies, we searched ClinicalTrials.gov, the German study register and the WHO registry. Results: In total, we identified six randomized controlled trials (RCT) with 1.346 patients, 26 prospective (with 1.366 patients) and 24 retrospective studies (with 2.629 patients). Of these, only six studies (one completed and one ongoing RCT (with 447 patients), one completed and one ongoing prospective single arm study (with 65 patients), and two retrospective single arm studies (with 122 patients)) evaluated HCT-ASCT. Patient relevant outcomes such as progression-free and overall survival and (neuro-)toxicity were adequately considered across almost all studies. The current study pool is, however, not conclusive in terms of the most effective treatment options for elderly. Main limitations were (very) small sample sizes and heterogeneous patient populations in terms of age ranges (particularly in RCTs) limiting the applicability of the results to the target population (elderly). Conclusions: Although it has been shown that HCT-ASCT is probably a feasible and effective treatment option, this approach has never been investigated within a RCT including a wide range of elderly patients. A RCT comparing conventional (immuno) chemotherapy with HCT-ASCT is crucial to evaluate benefit and harms in an un-biased manner to eventually provide older PCNSL patients with the most effective treatment. Full article
(This article belongs to the Special Issue Central Nervous System Malignant Lymphoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop